Population Pharmacokinetics of Temozolomide in Cancer Patients
- 1 January 2000
- journal article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 17 (10) , 1284-1289
- https://doi.org/10.1023/a:1026403805756
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and Its Interaction with DNABiochemistry, 1994
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)British Journal of Cancer, 1992
- Comparison of the cytotoxicity in vitro of temozolomide and dacarbazine, prodrugs of 3-methyl-(triazen-1-yl)imidazole-4-carboxamideCancer Chemotherapy and Pharmacology, 1991
- Characterisation of urinary metabolites of temozolomide in humans and mice and evaluation of their cytotoxicityCancer Chemotherapy and Pharmacology, 1990
- Antitumour imidazotetrazines—XVIIIBiochemical Pharmacology, 1989
- Antitumour imidazotetrazines—XVIBiochemical Pharmacology, 1987
- Antitumour imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one, a novel broad-spectrum antitumor agentJournal of Medicinal Chemistry, 1984
- Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: Routine clinical pharmacokinetic dataJournal of Pharmacokinetics and Biopharmaceutics, 1983
- Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic dataJournal of Pharmacokinetics and Biopharmaceutics, 1981
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976